Previous reports of these nanoconjugates have stated its ability to inhibit glioma tumor growth and angiogenesis [58], and a variant of the nanoconjugate has also been shown to inhibit tumor growth in HER2 positive breast cancers [58]. Here, ERBB2 is linked to breast cancer.